Hoth Therapeutics and Silo Pharma Form Joint Venture to Develop VA-Licensed GDNF-Based Obesity Treatment
Key Insights
Hoth Therapeutics and Silo Pharma (search) announced a 50/50 joint venture to develop a first-in-class obesity (search) treatment based on GDNF (search) technology exclusively licensed from the U.S. Department of Veterans Affairs (search).
The therapeutic platform targets the $100+ billion global obesity (search) market and focuses on treating obesity, non-alcoholic fatty liver disease (search), and type 2 diabetes (search) using VA-invented biologic technology.
GDNF (search) has demonstrated anti-obesity (search) effects and metabolic regulation in preclinical models, with the technology protected under U.S. Patent No. 10,052,362.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma (search), Inc. (NASDAQ: SILO) have announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity (search) and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (search) (VA).
The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (search) (GDNF (search)), a VA-invented biologic with demonstrated anti-obesity (search) effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions including non-alcoholic fatty liver disease (search) (NAFLD), type 2 diabetes (search), and central obesity.
Market Opportunity and Unmet Medical Need
The partnership targets the $100+ billion global obesity (search) market, addressing a critical unmet medical need. Obesity affects over 40% of U.S. adults and serves as a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care.
"This VA-originated obesity (search) technology has the potential to disrupt a $100B+ market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders," said Robb Knie, CEO of Hoth Therapeutics.
Strategic Partnership Structure
The collaboration establishes a 50/50 joint venture structure with equal equity and governance participation between both companies. The partnership secures an exclusive U.S. license from the U.S. Department of Veterans Affairs (search) covering all fields of use, with obesity (search) and NAFLD serving as the lead indication.
"With obesity (search) at epidemic levels and no curative therapies available, we believe GDNF (search) is a game-changer," said Eric Weisblum, CEO of Silo Pharma (search). "This collaboration with Hoth and the VA aligns with our mission to accelerate groundbreaking science into human trials."
Technology Platform and Therapeutic Approach
The GDNF (search)-based platform represents a novel approach to treating obesity (search) by targeting what the companies describe as the neuroinflammatory root of the condition. Currently, there are no approved curative biologics targeting this mechanism, positioning the VA-originated technology to fill a significant therapeutic gap.
The strategic alignment leverages the clinical infrastructure and public mission of the VA, Hoth's regulatory and development expertise, and Silo's translational capabilities and capital efficiency.
Market Response
Following the announcement, shares of Hoth Therapeutics rose 3% in pre-market trading, reflecting investor interest in the obesity (search) treatment opportunity and the exclusive licensing arrangement with the VA.